Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination.

Solomon B

Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Tel-Aviv 69978, Israel. beka@post.tau.ac.il

The pathology of Alzheimer's disease (AD) shows a significant correlation between beta-amyloid peptide (betaAP) deposition and the clinical severity of dementia. The ability of site-directed antibodies towards the N-terminal region of beta-amyloid peptide to suppress in vitro formation of toxic beta-amyloid serves as a factual basis for in vivo investigations. We localized the epitope of these anti-aggregating antibodies, and injection of phage displaying this epitope induced antibodies against the whole anti-beta-amyloid peptide. In Alzheimer's diseased transgenic mice, these antibodies are delivered from the periphery to the CNS preventing beta-amyloid formation and/or dissolving such aggregates. Performance of such antigens opens up possibilities for development of an efficient, long-lasting immunization procedure for treatment of Alzheimer's disease.

Published 9 March 2005 in Vaccine, 23(17): 2327-30.
Full-text of this article is available online (may require subscription).

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.